Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2015 06:15 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain

PALATINE, IL--(Marketwired - February 05, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of their second pseudoephedrine (PSE) product, NEXAFED® Sinus Pressure +...
January 08, 2015 06:00 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology

PALATINE, IL--(Marketwired - January 08, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the...
December 23, 2014 06:00 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy

PALATINE, IL--(Marketwired - December 23, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine...
December 08, 2014 06:30 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations

PALATINE, ILL--(Marketwired - December 08, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has...
November 03, 2014 16:30 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Announces Third Quarter 2014 Financial Results

PALATINE, IL--(Marketwired - November 03, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse,...
October 28, 2014 11:11 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals to Host Third Quarter 2014 Financial Results Conference Call on November 4, 2014

PALATINE, IL--(Marketwired - October 28, 2014) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company...
October 16, 2014 06:00 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Provides Update on Its Hydrocodone Bitartrate With Acetaminophen Tablets Development

PALATINE, IL--(Marketwired - October 16, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today that the US Food and Drug Administration (FDA) has denied on procedural grounds Acura's...
September 29, 2014 06:00 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints

PALATINE, IL--(Marketwired - Sep 29, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announced today preliminary results from three clinical studies for its abuse deterrent AVERSION®...
September 15, 2014 06:00 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Submits Formal Dispute Resolution Request With FDA Regarding Hydrocodone Bitartrate With Acetaminophen Tablets

PALATINE, IL--(Marketwired - Sep 15, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has submitted a formal dispute resolution request with the FDA for Vycavert®,...
August 27, 2014 06:15 ET | Source: Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals Receives Grant From National Institutes of Health to Fund Limitx(TM) Novel Abuse Deterrent Technology

PALATINE, IL--(Marketwired - Aug 27, 2014) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it has been awarded a $300,000 grant (the "Grant") by the National Institute On Drug...